The Edogawa-NICHE Committee recently announced that the 2019-Edogawa NICHE Prize has been awarded to Steven A. Rosenberg, MD, PhD, for his work in developing effective adoptive immunotherapies and genetically modified T cells. Dr. Rosenberg’s research has significantly contributed to the development of several immune system-based drugs and clinically effective immunotherapies, including chimeric antigen receptor T-cell therapy.
Steven A. Rosenberg, MD, PhD
Dr. Rosenberg epitomizes the significance of interdisciplinary interaction in developing clinical solutions. After earning his medical degree from Johns Hopkins University, he obtained a doctorate in biophysics. Dr. Rosenberg now leads an interdisciplinary team devoted to finding novel solutions to cancer, as Chief of the Surgery Branch at the National Cancer Institute and Professor of Surgery at the Uniformed Services University of Health Sciences and the George Washington University School of Medicine and Health Science.
Instituted in 2018 by the Jinseisha Trust, which owns Edogawa Hospital, Tokyo, and Nichi-In Centre for Regenerative Medicine, the Edogawa-NICHE Prize honors scientists or clinicians whose contributions lead to the development of prevention, diagnosis, or treatment of any disease, through interdisciplinary interaction. ■
